Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS

Journal of Lipid Research

Volumn 53, Issue 3, 2012, Pages 481-493

  Fanelli, Flaminia ^a   Di Lallo, Valentina D ^a   Belluomo, Ilaria ^a   De Iasio, Rosaria ^b   Baccini, Margherita ^a   Casadio, Elena ^a   Gasparini, Daniela Ibarra ^a   Colavita, Michelangelo ^a   Gambineri, Alessandra ^a   Grossi, Gabriele ^b   Vicennati, Valentina ^a   Pasquali, Renato ^a   Pagotto, Uberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Endocannabinoids; Reference intervals; Validation

Indexed keywords

1 ARACHIDONOYLGLYCEROL; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; N OLEOYLETHANOLAMINE; PALMIDROL; TOLUENE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLIC PARAMETERS; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PURIFICATION; REFERENCE VALUE; RELIABILITY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TWO DIMENSIONAL LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; ARACHIDONIC ACIDS; CHROMATOGRAPHY, LIQUID; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MONOGLYCERIDES; OLEIC ACIDS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84857754496     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M021378     Document Type: Article

References (47)

1. Devane, W. A., L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258: 1946-1949. (Pubitemid 23026736)
2. Mechoulam, R., S. Ben-Shabat, L. Hanus, M. Ligumsky, N. E. Kaminski, A. R. Schatz, A. Gopher, S. Almog, B. R. Martin, D. R. Compton, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50: 83-90.
3. Sugiura, T., S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215: 89-97.
4. Bisogno, T., F. Piscitelli, and V. Di Marzo. 2009. Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics. Eur. J. Lipid Sci. Technol. 111: 53-63.
5. Lo Verme, J., J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, and D. Piomelli. 2005. The nuclear receptor peroxisome proliferator- activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67: 15-19. (Pubitemid 40069962)
6. Guzmán, M., J. Lo Verme, J. Fu, F. Oveisi, C. Blázquez, and D. Piomelli. 2004. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J. Biol. Chem. 279: 27849-27854. (Pubitemid 38900052)
7. Hillard, C. J., K. M. Weinlander and K. L. Stuhr. 2011. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. Epub ahead of print. November 17, 2011.
8. Bari, M., N. Battista, V. Pirazzi, and M. Maccarrone. 2011. The manifold actions of endocannabinoids on female and male reproductive events. Front. Biosci. 16: 498-516.
9. Di Marzo, V., M. Côté, I. Matias, I. Lemieux, B. J. Arsenault, A. Cartier, F. Piscitelli, S. Petrosino, N. Alméras, and J. P. Després. 2009. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 52: 213-217.
10. Pagotto, U., G. Marsicano, D. Cota, B. Lutz, and R. Pasquali. 2006. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27: 73-100. (Pubitemid 43228239)
11. Quarta, C., R. Mazza, S. Obici, R. Pasquali, and U. Pagotto. 2011. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol. Med. 17: 518-526.
12. Zoerner, A. A., F. M. Gutzki, S. Batkai, M. May, C. Rakers, S. Engeli, J. Jordan, and D. Tsikas. 2011. Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. Biochim. Biophys. Acta. 1811: 706-723.
13. Rouzer, C. A., K. Ghebreselasie, and L. J. Marnett. 2002. Chemical stability of 2-arachidonylglycerol under biological conditions. Chem. Phys. Lipids. 119: 69-82. (Pubitemid 35247918)
14. Vogeser, M., D. Hauer, S. Christina Azad, E. Huber, M. Storr, and G. Schelling. 2006. Release of anandamide from blood cells. Clin. Chem. Lab. Med. 44: 488-491.
15. Vogeser, M., and G. Schelling. 2007. Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples. Clin. Chem. Lab. Med. 45: 1023-1025. (Pubitemid 47424862)
16. Higuchi, S., K. Irie, T. Nakano, Y. Sakamoto, Y. Akitake, M. Araki, M. Ohji, R. Furuta, M. Katsuki, R. Yamaguchi, et al. 2010. Reducing acyl migration during purification of 2-arachidonoylglycerol from biological samples before gas chromatography mass spectrometry analysis. Anal. Sci. 26: 1199-1202.
17. Skonberg, C., A. Artmann, C. Cornett, S. H. Hansen, and H. S. Hansen. 2010. Pitfalls in the sample preparation and analysis of N-acylethanolamines. J. Lipid Res. 51: 3062-3073.
18. Zoerner, A. A., S. Batkai, M. T. Suchy, F. M. Gutzki, S. Engeli, J. Jordan, and D. Tsikas. 2011. Simultaneous UPLC-MS/MS quantifi cation of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: Minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J. Chromatogr. B Analyt Technol Biomed Life Sci. Epub ahead of print. June 22, 2011.
19. US FDA. 2001. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, USA.
20. Henderson, M., and C. P. Freeman. 1987. A self-rating scale for bulimia. The 'BITE'. Br. J. Psychiatry. 150: 18-24.
21. Beck, A. T., C. H. Ward, M. Mendelson, J. Mock, and J. Erbaugh. 1961. An inventory for measuring depression. Arch. Gen. Psychiatry. 4: 561-571.
22. Gormally, J., S. Black, S. Daston, and D. Rardin. 1982. The assessment of binge eating severity among obese persons. Addict. Behav. 7: 47-55. (Pubitemid 12131037)
23. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
24. Wang, L., J. Liu, J. Harvey-White, A. Zimmer, and G. Kunos. 2003. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc. Natl. Acad. Sci. USA. 100: 1393-1398. (Pubitemid 36184012)
25. Centonze, D., L. Battistini, and M. Maccarrone. 2008. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr. Pharm. Des. 14: 2370-2382.
26. Engeli, S., J. Böhnke, M. Feldpausch, K. Gorzelniak, J. Janke, S. Bátkai, P. Pacher, J. Harvey-White, F. C. Luft, A. M. Sharma, et al. 2005. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 54: 2838-2843. (Pubitemid 41401077)
27. Blüher, M., S. Engeli, N. Klöting, J. Berndt, M. Fasshauer, S. Bátkai, P. Pacher, M. R. Schön, J. Jordan, and M. Stumvoll. 2006. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 55: 3053-3060. (Pubitemid 44923642)
28. Côté, M., I. Matias, I. Lemieux, S. Petrosino, N. Alméras, J. P. Després, and V. Di Marzo. 2007. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. (Lond). 31: 692-699. (Pubitemid 46482358)
29. Di Marzo, V., A. Verrijken, A. Hakkarainen, S. Petrosino, I. Mertens, N. Lundbom, F. Piscitelli, J. Westerbacka, A. Soro-Paavonen, I. Matias, et al. 2009. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur. J. Endocrinol. 161: 715-722.
30. Sipe, J. C., T. M. Scott, S. Murray, O. Harismendy, G. M. Simon, B. F. Cravatt, and J. Waalen. 2010. Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE. 5: e8792.
31. Patel, S., E. J. Carrier, W. S. Ho, D. J. Rademacher, S. Cunningham, D. S. Reddy, J. R. Falck, B. F. Cravatt, and C. J. Hillard. 2005. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J. Lipid Res. 46: 342-349. (Pubitemid 40271098)
32. Giuffrida, A., F. Rodríguez de Fonseca, and D. Piomelli. 2000. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 280: 87-93. (Pubitemid 30210816)
33. Schelling, G., D. Hauer, S. C. Azad, M. Schmoelz, A. Chouker, M. Schmidt, C. Hornuss, M. Rippberger, J. Briegel, M. Thiel, et al. 2006. Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology. 104: 273-277.
34. Wood, J. T., J. S. Williams, L. Pandarinathan, A. Courville, M. R. Keplinger, D. R. Janero, P. Vouros, A. Makriyannis, and C. J. Lammi-Keefe. 2008. Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin. Chem. Lab. Med. 46: 1289-1295.
35. Jian, W., R. Edom, N. Weng, P. Zannikos, Z. Zhang, and H. Wang. 2010. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878: 1687-1699.
36. Quercioli, A., Z. Pataky, G. Vincenti, V. Makoundou, V. Di Marzo, F. Montecucco, S. Carballo, A. Thomas, C. Staub, S. Steffens, et al. 2011. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur. Heart J. 32: 1369-1378.
37. Matias, I., M. P. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, C. Cervino, S. Petrosino, L. Hoareau, F. Festy, R. Pasquali, et al. 2006. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91: 3171-3180. (Pubitemid 44271774)
38. Cota, D., M. H. Tschöp, T. L. Horvath, and A. S. Levine. 2006. Cannabinoids, opioids and eating behaviour: the molecular face of hedonism? Brain Res. Rev. 51: 85-107. (Pubitemid 43782532)
39. De Marchi, N., L. De Petrocellis, P. Orlando, F. Daniele, F. Fezza, and V. Di Marzo. 2003. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2: 5.
40. Lutz, B. 2009. Endocannabinoid signals in the control of emotion. Curr. Opin. Pharmacol. 9: 46-52.
41. Monteleone, P., I. Matias, V. Martiadis, L. De Petrocellis, M. Maj, and V. Di Marzo. 2005. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 30: 1216-1221. (Pubitemid 40720981)
42. Hill, M. N., G. E. Miller, W. S. Ho, B. B. Gorzalka, and C. J. Hillard. 2008. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 41: 48-53. (Pubitemid 351427522)
43. Jumpertz, R., T. Wiesner, M. Blüher, S. Engeli, S. Bátkai, H. Wirtz, A. Bosse-Henck, and M. Stumvoll. 2010. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea- specific role of oleoylethanolamide. Exp. Clin. Endocrinol. Diabetes. 118: 591-595.
44. Karasu, T., T. H. Marczylo, M. Maccarrone, and J. C. Konje. 2011. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum. Reprod. Update. 17: 347-361.
45. Schroeder, C., S. Batkai, S. Engeli, J. Tank, A. Diedrich, F. C. Luft, and J. Jordan. 2009. Circulating endocannabinoid concentrations during orthostatic stress. Clin. Auton. Res. 19: 343-346.
46. Gatta-Cherifi, B., I. Matias, M. Vallée, A. Tabarin, G. Marsicano, P. V. Piazza, and D. Cota. 2011. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int. J. Obes. Epub ahead of print. August 16, 2011; doi: .
47. Ruby, M. A., D. K. Nomura, C. S. Hudak, L. M. Mangravite, S. Chiu, J. E. Casida, and R. M. Krauss. 2008. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride- rich lipoproteins. Proc. Natl. Acad. Sci. USA. 105: 14561-14566.